Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer

Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC). Objective: Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARP...

Full description

Bibliographic Details
Main Authors:	Maria Ornella Nicoletto, Alessandra Baldoni, Francesco Cavallin, Andrea Grego, Cristina Falci, Margherita Nardin, Enzo Mammano, Eleonora Lai, Valter Torri
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-06-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231173181

Similar Items

Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors
by: Ciara C. O'Sullivan, et al.
Published: (2014-02-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
by: Shicheng Yang, et al.
Published: (2023-05-01)

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
by: Anna Jo Bodurtha Smith, et al.
Published: (2024-04-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
by: Francesca Bizzaro, et al.
Published: (2021-11-01)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
by: Olga Kondrashova, et al.
Published: (2018-09-01)

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
by: Liya Ding, et al.
Published: (2018-12-01)

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
by: Caterina Fumagalli, et al.
Published: (2019-10-01)

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
by: Nora Sahnane, et al.
Published: (2020-12-01)

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges
by: Laetitia Collet, et al.
Published: (2024-03-01)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
by: Valentina Tuninetti, et al.
Published: (2023-02-01)

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01)

Differential Sensitivity of Germline and Somatic <i>BRCA</i> Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
by: Julie A. Vendrell, et al.
Published: (2023-09-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
by: Z Ping Lin, et al.
Published: (2018-01-01)

A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01)

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
by: Khayal Gasimli, et al.
Published: (2022-09-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
by: Christina T. Grech, et al.
Published: (2022-09-01)

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01)

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
by: Saya L. Jacob, et al.
Published: (2020-05-01)

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
by: Ting Hong, et al.
Published: (2021-06-01)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Tacconi, E, et al.
Published: (2019)

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response
by: Aladdin Riad, et al.
Published: (2020-12-01)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Eliana MC Tacconi, et al.
Published: (2019-07-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

PARP Inhibitors in Breast and Ovarian Cancer
by: Samuel S. Y. Wang, et al.
Published: (2023-04-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
by: Shan Li, et al.
Published: (2021-10-01)

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
by: Matias A. Bustos, et al.
Published: (2023-11-01)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
by: Margherita Turinetto, et al.
Published: (2021-06-01)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
by: Reisländer, T, et al.
Published: (2019)

Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition
by: Zhang Zheng, et al.
Published: (2024-03-01)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
by: Diar Aziz, et al.
Published: (2021-08-01)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
by: Sayra Dilmac, et al.
Published: (2023-07-01)

PARP Inhibitors for Breast Cancer: Germline <em>BRCA1/2</em> and Beyond
by: Maria Clara Saad Menezes, et al.
Published: (2022-09-01)

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
by: Fengqin Yan, et al.
Published: (2023-02-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
by: Geoffrey I Shapiro, et al.
Published: (2023-11-01)